Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

A Drug-Drug Interaction Study of Ibrutinib with Moderate and Strong CYP3A Inhibitors in Patients with B-Cell Malignancy

Jan de Jong, PhD, Peter Hellemans, MD, Severijn De Wilde, Daniel Patricia, Tara Masterson, Georgii Manikhas, MD PhD, Alexander Myasnikov, MD PhD, Dzhelil Osmanov, MD, Raul Cordoba, MD PhD, Carlos Panizo, Loeckie de Zwart, PhD, Jan Snoeys, PhD, Vijay Chauhan, PhD, James Jiao, PhD, Juthamas Sukbuntherng, PhD, Daniele Ouellet, PhD

Blood (2016) 128 (22): 3964.

https://doi.org/10.1182/blood.V128.22.3964.3964

Published: 2016

Journal Articles

An Open-Label, Sequential-Design Drug Interaction Study of the Effects of Omeprazole on the Pharmacokinetics of Ibrutinib in Healthy Adults

Jan de Jong, PhD, Peter Hellemans, MD, James Jiao, PhD, Juthamas Sukbuntherng, PhD, Daniele Ouellet, PhD

Blood (2016) 128 (22): 1588.

https://doi.org/10.1182/blood.V128.22.1588.1588

Published: 2016

Journal Articles

Open-Label, Multicenter, Dose Escalation Phase 1b Study to Assess the Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (PAVO)

Saad Z Usmani, MD FACP, Hareth Nahi, Maria-Victoria Mateos, MD PhD, Henk M. Lokhorst, MD PhD, Ajai Chari, MD, Jonathan L. Kaufman, MD, Philippe Moreau, Albert Oriol, MD, Torben Plesner, Professor, Lotfi Benboubker, MD PhD, Peter Hellemans, MD, Tara Masterson, Pamela L Clemens, PhD, Tahamtan Ahmadi, MD, Kevin Liu, Jesús San-Miguel, MD PhD

Blood (2016) 128 (22): 1149.

https://doi.org/10.1182/blood.V128.22.1149.1149

Published: 2016

Journal Articles

Phase 1b Dose Escalation Study Of Oral Quisinostat, a Histone Deacetylase Inhibitor (HDACi), In Combination With Velcade (Bortezomib) and Dexamethasone For Patients With Relapsed Multiple Myeloma (MM)

Philippe Moreau, MD, Thierry Facon, MD, Cyrille Touzeau, MD, Lotfi Benboubker, MD, Martine Delain, MD, Julie Badamo-Dotzis, PhD, Charles Phelps, Christopher Doty, Hans Smit, PhD, Nele Fourneau, MD, Ann Forslund, Peter Hellemans, MD, Xavier Leleu, MD, PhD

Blood (2013) 122 (21): 1932.

https://doi.org/10.1182/blood.V122.21.1932.1932

Published: 2013

Journal Articles

Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP): Updated Results From a Phase 1b Study In Treatment-Naïve Patients With CD20-Positive B-Cell Non-Hodgkin’s Lymphoma (NHL)

Anas Younes, MD, Ian Flinn, MD, PhD, Jesus Berdeja, MD, Jonathan W. Friedberg, MD, Carla Casulo, MD, Catherine Thieblemont, MD, PhD, Franck Morschhauser, MD, PhD, Jason R. Westin, MD, Shobha Seetharam, PhD, Peter Hellemans, MD, Hans Smit, PhD, Ronald de Vries, MSc, Elisa Dauphinee, BSN, CRA, CCRP, Julie Badamo-Dotzis, PhD, Nele Fourneau, MD, Yasuhiro Oki, MD

Blood (2013) 122 (21): 852.

https://doi.org/10.1182/blood.V122.21.852.852

Published: 2013

Journal Articles

Phase 2 Multicenter Trial of Oral Quisinostat, a Histone Deacetylase Inhibitor, in Patients with Previously Treated Stage IB-IVA Cutaneous T-Cell Lymphoma

Fiona Child, MD, Pablo Ortiz Romero, Prof., Rute Alvarez, MD, Martine Bagot, Rudolf Stadler, MD, Michael Weichenthal, MD, Rosario Alves, MD, Maria Grazia Bernengo, Prof., Marie Beylot-Barry, Prof., Richard Cowan, Larisa J. Geskin, MD, Amparo Pérez Ferriols, Peter Hellemans, MD, Yusri Elsayed, MD, PhD, Charles Phelps, Ann Forslund, Makio Kamida, Pier Luigi Zinzani, MD

Blood (2012) 120 (21): 3676.

https://doi.org/10.1182/blood.V120.21.3676.3676

Published: 2012

NARROW

A Drug-Drug Interaction Study of Ibrutinib with Moderate and Strong CYP3A Inhibitors in Patients with B-Cell Malignancy

An Open-Label, Sequential-Design Drug Interaction Study of the Effects of Omeprazole on the Pharmacokinetics of Ibrutinib in Healthy Adults

Open-Label, Multicenter, Dose Escalation Phase 1b Study to Assess the Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (PAVO)

Phase 1b Dose Escalation Study Of Oral Quisinostat, a Histone Deacetylase Inhibitor (HDACi), In Combination With Velcade (Bortezomib) and Dexamethasone For Patients With Relapsed Multiple Myeloma (MM)

Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP): Updated Results From a Phase 1b Study In Treatment-Naïve Patients With CD20-Positive B-Cell Non-Hodgkin’s Lymphoma (NHL)

Phase 2 Multicenter Trial of Oral Quisinostat, a Histone Deacetylase Inhibitor, in Patients with Previously Treated Stage IB-IVA Cutaneous T-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

A Drug-Drug Interaction Study of Ibrutinib with Moderate and Strong CYP3A Inhibitors in Patients with B-Cell Malignancy

An Open-Label, Sequential-Design Drug Interaction Study of the Effects of Omeprazole on the Pharmacokinetics of Ibrutinib in Healthy Adults

Open-Label, Multicenter, Dose Escalation Phase 1b Study to Assess the Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (PAVO)

Phase 1b Dose Escalation Study Of Oral Quisinostat, a Histone Deacetylase Inhibitor (HDACi), In Combination With Velcade (Bortezomib) and Dexamethasone For Patients With Relapsed Multiple Myeloma (MM)

Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP): Updated Results From a Phase 1b Study In Treatment-Naïve Patients With CD20-Positive B-Cell Non-Hodgkin’s Lymphoma (NHL)

Phase 2 Multicenter Trial of Oral Quisinostat, a Histone Deacetylase Inhibitor, in Patients with Previously Treated Stage IB-IVA Cutaneous T-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only